ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Solid Tumors
Ecaterina Dumbrava, MD
MD Anderson Cancer Center


The protein, p53, is responsible for stopping cellular growth and inducing the self-destruction of unwanted cells. As a result, the gene encoding for p53, TP53, is classified as a tumor suppressor gene. Proteins such as MDM2 and MDMX can inhibit p53, allowing for uncontrolled cellular growth. Abnormally high levels of these proteins have been found in breast cancer. ALRN-6924 is a drug that disrupts the interaction between p53 and MDMX and MDM2, allowing p53 to function properly as a tumor suppressor. Preclinical studies have found ALRN-6924 in combination with paclitaxel, a chemotherapy, had a synergistic effect against breast cancer cells. This phase I study will establish the safety of ALRN-6924 in combination with paclitaxel in patients with advanced or metastatic solid tumors without a functional mutation in TP53.

Trial Registration: Identifier: NCT03725436